.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,602,215

« Back to Dashboard

Claims for Patent: 8,602,215

Title:Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
Abstract: The disclosure relates to a method for managing the risk of dronedarone/beta-blockers interaction by using dronedarone or pharmaceutically acceptable salts thereof in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted to reduce the risk of cardiovascular hospitalization, said patients also expecting to receive a beta-blockers treatment, by performing the following steps: a--initiate beta-blockers treatment at a low dose; b--performing a electrocardiogram (ECG) verification of good tolerability; c--increase of beta-blockers dose only if results in step b) are satisfying.
Inventor(s): Radzik; Davide (Paris, FR)
Assignee: Sanofi (Paris, FR)
Application Number:13/172,984
Patent Claims: 1. A method for managing the risk of dronedarone/beta-blocker interaction in a patient with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who is in sinus rhythm or who will be cardioverted to reduce the risk of cardiovascular hospitalization, said patient also expecting to receive a beta-blocker treatment, comprising administering dronedarone or a pharmaceutically acceptable salt thereof to said patient, and then performing the following steps: a--initiating beta-blocker treatment in said patient at a low dose; b--and then performing a electrocardiogram (ECG) assessment in said patient; and c--then increasing beta-blocker dose to said patient only if results in step b) verify good tolerability.

2. The method according to claim 1, wherein dronedarone is administered 400 mg twice daily with meals.

3. The method according to claim 1, wherein the pharmaceutically acceptable salt of dronedarone is hydrochloride.

4. The method according to claim 1, wherein in step b), the beta-blocker dose may be increased up to a fraction of the recommended dose higher than the low dose.

5. The method according to claim 1, wherein the beta-blocker is metoprolol.

6. The method according to claim 5, wherein the low dose of metoprolol is less than 200 mg.

7. The method according to claim 5, wherein the low dose of metoprolol is 100 mg.

8. The method according to claim 1, wherein the beta-blocker is propranolol.

9. The method according to claim 8, wherein the low dose of propranolol is less than 160 mg.

10. The method according to claim 8, wherein the low dose of propranolol is 40 mg.

11. The method according to claim 1, wherein good tolerability is indicated by a heart rate higher than 50 bpm.

12. The method according to claim 1, wherein good tolerability is indicated by a PR-interval shorter than 200 ms.

13. The method according to claim 1, wherein the patient has at least one associated cardiovascular risk factor selected from the group consisting of: i. an age greater than 70; ii. hypertension; iii. diabetes; iv. a prior cerebrovascular accident, v. a left atrial diameter greater than or equal to 50 mm; and vi. a left ventricular ejection fraction less than 40%.

14. The method according to claim 13, wherein the patient has hypertension.

15. The method according to claim 13, wherein the patient has diabetes.

16. The method according to claim 1, wherein the patient had an episode of atrial fibrillation or atrial flutter with the last 6 months.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc